Boston Scientific Corporation Profile and SWOT Analysis Report 2018

Report Name: Boston Scientific Corporation Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

Boston Scientific Corporation Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

Boston Scientific Corporation – Business Description:

Boston Scientific Corporation (Boston Scientific or ‘the company’) is engaged in the development, manufacture and marketing of less-invasive medical devices. It offers several products in the areas of interventional cardiology, cardiac rhythm management (CRM), endoscopy, peripheral interventions, urology and pelvic health, neuromodulation, and electrophysiology. The company operates in the US, Japan, and other countries. The company operates through three business segments: Cardiovascular; MedSurg; and Rhythm Management. The Cardiovascular business segment of the company offers its products through two business divisions: interventional cardiology; and peripheral intervention. Boston Scientific’s interventional cardiology business division develops and manufactures products used to diagnose and treat coronary artery disease and other cardiovascular disorders, including structural heart conditions. The company’s interventional cardiology products include coronary stents, including drug-eluting and bare metal stent systems, balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels, diagnostic catheters, and intravascular ultrasound (IVUS) imaging systems. Structural heart product offerings of the company include a device for transcatheter aortic valve replacement and a device designed to close the left atrial appendage in patients with atrial fibrillation that are at risk for ischemic stroke. The peripheral intervention business unit offers products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Peripheral product offerings portfolio consists of stents, balloon catheters, wires, peripheral embolization devices and other devices used to diagnose and treat peripheral vascular disease, along with products to treat, diagnose and ease various forms of cancer. The company also sells products designed to treat patients with non-vascular disease. The non-vascular products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. In FY2016, the Cardiovascular segment reported revenues of $3,617 million, which accounted for 43.1% of the company’s total revenue*. The MedSurg business segment of Boston Scientific offers its products through three business divisions: endoscopy; urology/pelvic health; and neuromodulation. The company’s endoscopy business division offers a range of pulmonary and gastrointestinal (GI) conditions. Common GI disease states include esophageal disorders, GI strictures and bleeding, pancreatico-biliary disease and other associated conditions, as well as esophageal, biliary, pancreatic and colon cancer. The division also offers interventional bronchoscopy devices which are used to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Boston Scientific’s urology/pelvic health business unit develops, manufactures and sells devices to treat various urological and pelvic conditions. Within its urology business, the company sells a variety of products designed to treat patients with urinary stone disease and benign prostatic hyperplasia (BPH). The company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters. Within its pelvic health business, the company markets a range of devices for the treatment of conditions such as stress urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), menorrhagia (excessive menstrual bleeding), and uterine fibroids and polyps. The company offers mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The company markets its Genesys Hydro ThermAblator (HTA) System, an ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia, and Symphion System for the removal of intrauterine fibroids and polyps. Under the neuro-modulation business division, the company markets the Precision and Precision Spectra spinal cord stimulator (SCS) system for the management of chronic pain. In FY2016, the Medsurg segment reported revenues of $3,204 million, which accounted for 38.2% of the company’s total revenue*. The company’s Rhythm Management business segment provides its products under two business division: cardiac rhythm management (CRM) and electrophysiology. The CRM business division develops, manufactures and markets a variety of implantable devices including implantable cardioverter defibrillator (ICD) systems, implantable cardiac resynchronization therapy defibrillators, and implantable pacemaker systems that monitor the heart and deliver electricity to treat cardiac abnormalities. The company’s electrophysiology business division develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Boston Scientific’s electrophysiology products include steerable radio frequency (RF) ablation catheters, intra-cardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. In FY2016, the Rhythm Management segment reported revenues of $2,255 million, which accounted for 26.9% of the company’s total revenue*. Geographically, the company classifies its operations into three segments, namely the US, Japan, and Other Countries. In FY2016, the US segment accounted for 56.7% of the company’s total revenues, followed by Japan with 8.9%; and Other Countries with 34.3%. * As reported by the company.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.

Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Balfour Beatty plcoperate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Balfour Beatty plcperformed financially from 2013?

How does Balfour Beatty plcrank among its peers in terms of revenue and market share?

What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report:Request Sample

Got Some Questions? Inquire Here:Inquire Before Buying

Get This Report:Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
+1 888 709 8757

Be the first to comment

Leave a Reply